FDA Releases Concept Paper on Pharmacogenomics
After nearly two years of receiving voluntary genomic data submissions as part of its pharmacogenomics guidance, the FDA has released a preliminary concept paper titled Pharmacogenomic Data Submissions.
After nearly two years of receiving voluntary genomic data submissions as part of its pharmacogenomics guidance, the FDA has released a preliminary concept paper titled Pharmacogenomic Data Submissions. The paper expands on the recommendations made in FDA’s guidance for industry on data submissions, issued in March 2005.
Based on its experience with voluntary genomic data submissions and with its review of numerous protocols and data submitted under investigational new drug applications, new drug applications, and biologics license applications during the last two years, FDA believes that guidance will benefit sponsors considering the submission of either voluntary genomic data or marketing applications containing genomics data.
The areas covered in the new document include gene expression data from microarrays including sections on RNA isolation, handling and characterization; labeling reactions, RNA labeling situations to be avoided; proficiency testing to avoid procedural failures; hybridizations for microarrays; fluorescence reader settings for microarrays; and differentially expressed genes and their biological interpretation.
The paper also elaborates on genotyping methods, and DNA isolation, handling and characterization. Genomic data in clinical study reports and from nonclinical toxicology studies, expanding the selection process criteria, and characterization of a particular compound are the other areas covered. A general scientific discussion concludes the paper.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
